Caroline Clairmont, Ph.D., spent 13 years at Bristol Myers Squibb (BMS) in research and development (R&D) operations. Dr. Clairmont’s most recent role was as head of regional R&D operations and schedule management, having responsibility across the BMS portfolio covering discovery to life cycle management. Prior to this position, Dr. Clairmont was responsible for the management of the specialty portfolio including cardiovascular, immunoscience, virology, fibrotic disease and genetically-defined diseases. She has also been involved with managing multiple licensing, partnering and acquisition opportunities.
Prior to joining BMS, Dr. Clairmont spent eight years at Vion Pharmaceuticals, starting as a research scientist in molecular and microbiology and ending her tenure as the director of quality control, analytical and bio-analytical development and manufacturing where she was responsible for all pre-clinical and clinical analytical development for biologics and small molecules as well as analysis of clinical samples and all operational logistics to support clinical pharmacokinetic / pharmacodynamics (PK/PD).
Dr. Clairmont has been published in multiple peer-reviewed journals, including Cancer Gene Therapy, Journal of Infectious Diseases and Proceedings of the National Academy of Sciences, and as an inventor on two patents from her work on the anti-cancer technology T.A.P.E.T. (Tumor Amplified Protein Expression Therapy).
Dr. Clairmont earned her bachelor of arts degree in biochemistry from Clark University and her doctor of philosophy degree in biochemistry and molecular biology from the University of Massachusetts Medical School and completed her post-doctoral work at Yale University. While at Yale, Dr. Clairmont helped to establish the Connecticut chapter for the Association for Women in Science and served as the organization’s president from 2001-2003.